Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
4.870
+0.190 (4.06%)
At close: Dec 20, 2024, 4:00 PM
4.760
-0.110 (-2.26%)
After-hours: Dec 20, 2024, 7:58 PM EST
Lipocine Employees
Lipocine had 17 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$466,054
Profits / Employee
-$238,593
Market Cap
26.04M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
DarioHealth | 294 |
HOOKIPA Pharma | 179 |
Pluri | 118 |
PolyPid | 62 |
Femasys | 34 |
Longeveron | 24 |
NeuroSense Therapeutics | 18 |
Akari Therapeutics, | 12 |
LPCN News
- 4 days ago - FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PRNewsWire
- 4 weeks ago - Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - PRNewsWire
- 6 weeks ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - PRNewsWire
- 7 weeks ago - Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea - PRNewsWire
- 2 months ago - Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results - PRNewsWire
- 2 months ago - Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries - PRNewsWire
- 2 months ago - Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - PRNewsWire
- 2 months ago - Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - PRNewsWire